Details for Patent: 6,046,183

Summary for Patent: 6,046,183

Title:	Method of synergistic treatment for benign prostatic hyperplasia
Abstract:	Disclosed is an improved treatment for men with benign prostatic hyperplasia (BPH), involving combination therapy of a 5.alpha.-reductase inhibitor, e.g. a 17.beta.-substituted 4-azasteroid, a 17.beta.-substituted non-azasteroid, 17.beta.-acyl-3-carboxy-androst-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and particularly finasteride, in combination with an .alpha..sub.1 -adrenergic receptor blocker, i.e., terazosin. The combination provides therapy at the molecular level for the underlying cause of the disease as well as providing symptomatic relief. Pharmaceutical compositions useful for treatment are also disclosed.
Inventor(s):	Gormley; Glenn J. (Westfield, NJ), Stoner; Elizabeth (Westfield, NJ)
Assignee:	Merck & Co., Inc. (Rahway, NJ)
Application Number:	09/027,105
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 6,046,183

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 6,046,183

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	1751492
Australia	666846
Bulgaria	61798
Bulgaria	98113